Ignite Creation Date:
2024-05-06 @ 6:57 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05846971
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-05-06
First Post:
2022-11-14
Brief Title:
Clinical Utility of Methylation-based Prognostic Assay for Barretts Esophagus
Sponsor:
Capsulomics Inc
Organization:
Capsulomics Inc
Study Overview
Official Title:
Clinical Utility of Methylation-based Prognostic Assay for Barretts Esophagus
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Capsulomics has developed a prognostic assay for patients with diagnosed Barretts esophagus BE This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different clinical and prognostic assay information
Detailed Description:
Capsulomics has developed a prognostic assay for patients with diagnosed Barretts esophagus BE This study will measure how gastroenterologists make surveillance and treatment management decisions for virtual patient cases when presented with different clinical and prognostic assay information The data from this study will be published in a peer-review scientific journal
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None